Listening...

Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. UK/
    2. Our innovation /
    3. Focus areas /
    4. Specialty Ophthalmology

    Specialty Ophthalmology

    jj-photo-grandmother-laughing-with-granddaughter-offset-819359-4star.jpg

    Our focus in specialty ophthalmology

    At Johnson & Johnson Innovative Medicine (J&J) UK, we are committed to advancing the treatment of retinal diseases that cause vision loss and impairment. This includes inherited retinal diseases (IRDs) and age-related macular degeneration (AMD), each presenting unique challenges and unmet needs.

    In the UK, conditions such as X-linked Retinitis Pigmentosa (XLRP) and geographic atrophy (GA), a late-stage form of AMD, significantly impact patients’ quality of life, often leading to legal blindness. Over 700,000 people in the UK are affected by AMD, and more than 25,000 are affected by inherited retinal dystrophies, including retinitis pigmentosa. 1,2,3 Despite this, treatment options, particularly for advanced stages, remain limited.

    Through ongoing research and innovation, we aim to provide effective solutions and improve outcomes for those living with these conditions.

    Innovating for better vision in ophthalmology

    Retinal diseases, such as AMD and IRDs, present significant challenges for both patients and the healthcare system. These conditions lead to vision impairment and place increasing strain on NHS resources, with limited treatment options for advanced stages.

    At J&J, we focus on addressing these challenges through innovative therapies and strong partnerships with healthcare professionals. Our research into gene therapies and novel treatments aims to improve patient outcomes, ease the burden on healthcare services, and help patients preserve their vision and quality of life.
    700,000
    People in the UK are impacted by AMD, with numbers increasing due to an aging population.1
    1 in 4,000
    People in the UK live with retinitis pigmentosa.4
    +26%
    Of people are estimated to be living with geographic atrophy, a late-stage form of AMD.5
    jj-photo-male-human-face-eye-closeup-gettyimages-949265660-4star.jpg

    Our mission in specialty ophthalmology

    At J&J, we are driven by a clear mission to improve the lives of those affected by blinding retinal diseases.

    Guided by courageous science, we are committed to advancing innovative treatments, including gene therapies, that aim to preserve and restore vision. Our focus remains on making meaningful progress to address the unmet needs of patients living with these conditions.
    jj-photo-lab-tech-inspecting-substance-in-bottle-im-1star.jpg
    How we work

    Partner with us

    We are committed to partnering with those whose innovative thinking will bring new and creative solutions to the field of medicine
    Reach out

    References
    1: Macular Society. Age-related macular degeneration (AMD). Available here: https://www.macularsociety.org/macular-disease/macular-conditions/age-related-macular-degeneration/ . Last accessed October 2025.
    2: Retina UK. Retinitis pigmentosa. Available here: https://retinauk.org.uk/information-and-support/about-inherited-sight-loss/types-of-inherited-sight-loss/classic-retinitis-pigmentosa. Last accessed October 2025.
    3: Retina UK. About inherited sight loss. Available here: https://retinauk.org.uk/information-and-support/about-inherited-sight-loss/ . Last accessed October 2025.
    4: Sight research UK. What Is Retinitis Pigmentosa?. Available here: https://www.sightresearchuk.org/conditions/retinitis-pigmentosa/ . Last accessed October 2025.
    5: NHS Health Research Authority. Burden of Illness in Geographic Atrophy in the UK, Germany and Ireland. Available here: https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/burden-of-illness-in-geographic-atrophy-in-the-uk-germany-and-ireland/ . Last accessed October 2025.

    CP-548119 | October 2025